SEATTLE--(BUSINESS WIRE)--Adaptive Biotechnologies today announced the appointment of Lance Baldo, M.D., as Chief Medical Officer. Dr. Baldo brings 20 years of experience in both technology and therapeutics, combined with expertise in organizational design and change, including his most recent role as Senior Vice President and Head of U.S. Medical Affairs at Genentech, Inc., a member of the Roche Group.
“Lance’s background and his experience at Genentech and Roche made him well suited for the role of Chief Medical Officer at Adaptive,” said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. “We are very pleased to welcome Lance to the Adaptive team as our company continues to grow.”
During Dr. Baldo’s tenure at Genentech, he oversaw the successful medical launch of a number of new medicines, including Hemlibra® (emicizumab-kxwh), a novel treatment for hemophilia A, and OCREVUS® (ocrelizumab), the first B-cell therapy specifically indicated for multiple sclerosis. Dr. Baldo also led the Medical Affairs division through an agile transformation, focusing on driving towards individual empowerment, broadening roles, and revamping the field medical team all in the service of better patient outcomes and customer engagement.
Before becoming Head of U.S. Medical Affairs, he was Franchise Head for Ophthalmology, overseeing the launch of two new indications for Lucentis. He was General Manager for Roche Pharma in New Zealand, and he also served as a Lifecycle Leader and as a Global Medical Director for Roche Global Product Strategy/Global Medical Affairs in Basel, Switzerland. Before joining Roche, Dr. Baldo was the Global Vice President of Medical Science and Affairs for The Medicines Company in Parsippany, NJ, and he founded a venture capital-backed medical software company MedAptus, Inc. where he was Chief Medical Officer and capital fundraiser.
“I am passionate about joining Adaptive as it has the potential to disrupt the paradigm of how diseases are diagnosed, monitored and treated,” said Dr. Baldo. “I look forward to working closely with Adaptive and Adaptive’s partners to continue to establish the company’s leadership in immune-driven medicine.”
About Adaptive Biotechnologies
Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems. Adaptive’s proprietary immune medicine platform reveals and translates insights from our adaptive immune systems with unprecedented scale and precision. Working with drug developers, clinicians and academic researchers, we are applying these insights to develop products that will transform the way diseases such as cancer, autoimmune conditions, and infectious diseases are diagnosed and treated. For more information, please visit adaptivebiotech.com.